ACRO Biomedical Business Summary

ACRO Biomedical (6748.TWO) is a leading Taiwanese regenerative medicine company that generates revenue through the development and commercialization of biomaterial-based medical devices and decellularized tissue scaffolds. Utilizing its proprietary supercritical carbon dioxide (scCO2) extraction platform, the company removes cellular components and lipids from porcine tissues to create high-purity collagen scaffolds that preserve natural structural integrity and minimize host immune rejection. Its primary business segments encompass wound care (ABCcolla® Collagen Matrix), orthopedics (bone grafts), dentistry (collagen membranes), and ophthalmology (corneal matrix), with emerging revenue streams from out-licensing, ODM/OEM services, and bionic research involving brain-machine interfaces. In the global regenerative medicine market, ACRO Biomedical competes with major players such as Integra LifeSciences, Smith & Nephew, Organogenesis, and local rival Sunmax Biotechnology, positioning itself as a high-tech niche innovator through its unique chemical-free decellularization process. The company was founded in June 2014 by a multidisciplinary team of scientists and physicians led by Dr. Dar-Jen Hsieh, who serves as the current Chairman and CEO. Dr. Hsieh holds a Ph.D. in Cell and Molecular Biology from the State University of New York at Buffalo and brings over 30 years of industry expertise, including previous leadership roles as CEO of Sunmax Biotechnology and research positions at the Animal Technology Institute Taiwan. The leadership team is supported by a Scientific Advisory Board and maintains strategic international alliances with partners such as Marubeni in Japan and Oculus BioMed in Australia. The company’s board is focused on scaling its "whole-organ engineering" initiatives, targeting the reconstruction of functional human organs to address global donor shortages.